Should pot policy be based on its potency?
Public health: Some states are setting new rules on pot sales and tax policy based on the product’s potency.
As marijuana legalization spreads across U.S. states, so does a debate over whether to set pot policy by potency.
Under a law signed last month, New York will tax recreational marijuana based on its amount of THC, the main intoxicating chemical in cannabis. Illinois imposed a potency-related tax when recreational pot sales began last year. Vermont is limiting THC content when its legal market opens as soon as next year, and limits or taxes have been broached in some other states and the U.S. Senate’s drug-control caucus.
Supporters say such measures will protect public health by roping off, or at least discouraging, what they view as dangerously concentrated cannabis.
“This is not your Woodstock weed,” says Kevin Sabet, the president of Smart Approaches to Marijuana, an anti-legalization group that has been pressing for potency caps. “We need to put some limitations on the products being sold.”
‘Prohibitionism’
Opponents argue that THC limits could drive people to buy illegally, and amount to beginning to ban pot again over a concern that critics see as overblown.
“It’s prohibitionism 2.0,” said Cristina Buccola, a cannabis business lawyer in New York. “Once they start putting caps on that, what don’t they put caps on?”
THC levels have been increasing in recent decades — from 4% in 1995 to 12% in 2014 in marijuana seized by federal agents, for example. Cannabis concentrates sold in Colorado’s legal market average about 69% THC, and some top 90%, according to state reports.
A sweeping 2017 examination of cannabis and health by the National Academies of Sciences, Engineering, and Medicine listed increasing potency among factors that “create the potential for an increased risk of adverse health effects.”
Some studies have linked high-THC pot, especially when used daily, with the likelihood of psychosis and certain other mental health problems. But there is debate over whether one causes the other.
Dr. Rachel Knox, an Oregon physician who counsels patients on using cannabis for various conditions, says she doesn’t see an increased risk of psychosis for people using such products under medical oversight. She opposes capping potency but suggests that products containing over 70% THC should be reserved for medical users while research continues.
“I think we should treat it with both freedom and with kid gloves,” says Knox, a former chair of the Oregon Cannabis Commission and a board member of the Minority Cannabis Business Association, a trade group.
Public health
But Colorado pediatrician and state Rep. Dr. Yadira Caraveo says she has seen the dangers of highTHC cannabis.
One of her adolescent patients who used highpotency pot daily was repeatedly hospitalized with severe vomiting linked to heavy marijuana use, and another needed psychiatric hospitalization after the drug exacerbated his mental health problems, said Caraveo. She’s thinking about proposing a potency cap.
“I’m not interested in going back to criminalization,” the Democrat says, but “the reason that I ran, and what I continue to do with the Legislature every day, is to protect public health.”
Various states have regulated how many milligrams of THC can be in a single serving, package or retail sale, at least for some products. Vermont took a different approach, limiting the percentage of the chemical in any amount of recreational pot — 30% for flower-form marijuana and 60% for concentrates.
Virginia’s new legalization law gives its future Cannabis Control Authority the power to set THC limits, and a proposal to cap THC in medical marijuana has gotten some attention in Florida’s Legislature. Nationally, the U.S. Senate’s bipartisan Caucus on International Narcotics Control suggested last month that federal health agencies study whether pot potency should be limited.
Legalization supporters say caps will backfire.
“Consumer demand for these products is not going to go away, and re-criminalizing them will only push this consumer base to seek out similar products in the unregulated illicit market,” Paul Armentano, the deputy director of NORML, wrote in a recent op-ed in the Denver newspaper Westword.